- Home
- CUE vs VTVT Comparison
CUE vs VTVT Comparison
Compare CUE & VTVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CUE
- VTVT
- Stock Information
- Founded
- CUE 2014
- VTVT 2015
- Country
- CUE United States
- VTVT United States
- Employees
- CUE N/A
- VTVT N/A
- Industry
- CUE Biotechnology: Pharmaceutical Preparations
- VTVT Biotechnology: Pharmaceutical Preparations
- Sector
- CUE Health Care
- VTVT Health Care
- Exchange
- CUE Nasdaq
- VTVT Nasdaq
- Market Cap
- CUE 58.9M
- VTVT 56.7M
- IPO Year
- CUE 2018
- VTVT 2015
- Fundamental
- Price
- CUE $0.64
- VTVT $16.48
- Analyst Decision
- CUE Strong Buy
- VTVT Strong Buy
- Analyst Count
- CUE 3
- VTVT 2
- Target Price
- CUE $3.00
- VTVT $35.50
- AVG Volume (30 Days)
- CUE 163.7K
- VTVT 5.8K
- Earning Date
- CUE 05-12-2025
- VTVT 05-15-2025
- Dividend Yield
- CUE N/A
- VTVT N/A
- EPS Growth
- CUE N/A
- VTVT N/A
- EPS
- CUE N/A
- VTVT N/A
- Revenue
- CUE $7,991,000.00
- VTVT $17,000.00
- Revenue This Year
- CUE N/A
- VTVT N/A
- Revenue Next Year
- CUE $25.99
- VTVT N/A
- P/E Ratio
- CUE N/A
- VTVT N/A
- Revenue Growth
- CUE 13.83
- VTVT N/A
- 52 Week Low
- CUE $0.45
- VTVT $12.12
- 52 Week High
- CUE $1.99
- VTVT $26.99
- Technical
- Relative Strength Index (RSI)
- CUE 37.72
- VTVT 34.47
- Support Level
- CUE $0.61
- VTVT $15.91
- Resistance Level
- CUE $0.71
- VTVT $18.09
- Average True Range (ATR)
- CUE 0.06
- VTVT 1.06
- MACD
- CUE -0.00
- VTVT -0.68
- Stochastic Oscillator
- CUE 17.84
- VTVT 0.00
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.
About VTVT vTv Therapeutics Inc.
vTv Therapeutics Inc is a clinical stage biopharmaceutical company focused on the development of orally administered treatments for metabolic and inflammatory diseases to minimize their long-term complications and improve the lives of patients. Its product pipeline include TTP399, TTP273, HPP737, HPP593, Azeliragon, HPP971, HPP3033, and TTP-RA.